BXM Wealth LLC Has $394,000 Position in Amgen Inc. $AMGN

BXM Wealth LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 95.9% in the first quarter, Holdings Channel reports. The firm owned 1,119 shares of the medical research company’s stock after selling 26,121 shares during the quarter. BXM Wealth LLC’s holdings in Amgen were worth $394,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in Amgen during the fourth quarter worth about $2,164,162,000. Capital World Investors lifted its stake in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. State Street Corp grew its position in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares during the period. Geode Capital Management LLC raised its position in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. Finally, Amundi raised its position in shares of Amgen by 41.1% in the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock valued at $1,111,854,000 after acquiring an additional 988,856 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research note on Thursday, March 5th. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada reiterated a “positive” rating on shares of Amgen in a research report on Thursday, June 18th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $354.42.

Amgen Price Performance

Amgen stock opened at $360.55 on Tuesday. The stock has a 50-day moving average price of $340.92 and a two-hundred day moving average price of $346.71. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a market capitalization of $194.59 billion, a PE ratio of 25.09, a P/E/G ratio of 3.60 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the company earned $4.90 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts expect that Amgen Inc. will post 22.38 EPS for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.